[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) in a deal worth up to $2.6B. Under the agreement, Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) will receive exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macau, and Taiwan.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.